Medication info
Sitaphol MXR Sustained-Release Tablets 100/1000 mg

Sitaphol MXR Sustained-Release Tablets 100/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.4mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Mothers Pharmaceutical Co., Ltd.
Appearance
Bright blue, oval-shaped, biconvex sustained-release film-coated tablets
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202202002 · Approved 2022.05.12 · Insurance code 622804880

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2. Contraindications in the Precautions for Use). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient’s existing metformin dose. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their existing doses of sitagliptin and metformin. - Patients receiving immediate-release metformin at an existing dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablet once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined taking the patient’s blood glucose level and existing dose into consideration. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5. General Precautions in the Precautions for Use). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2. Contraindications in the Precautions for Use).

Ingredients

Manufacturer
Mothers Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication contains sitagliptin and metformin, helping patients with type 2 diabetes achieve better blood sugar control alongside dietary and exercise therapies. It aids in stabilizing blood sugar levels in conjunction with lifestyle modifications, thus assisting in the management of diabetes.

How to take

Adult dose

The dose of this medicine for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2. Contraindications in the Precautions for Use). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient’s existing metformin dose. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their existing doses of sitagliptin and metformin. - Patients receiving immediate-release metformin at an existing dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablet once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined taking the patient’s blood glucose level and existing dose into consideration. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5. General Precautions in the Precautions for Use). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2. Contraindications in the Precautions for Use).

Precautions

This medication is a combination drug containing sitagliptin and metformin, primarily used for blood sugar control in patients with type 2 diabetes. Serious allergic reactions may occur during treatment, so if symptoms such as rash, hives, difficulty breathing, or swelling of the face or neck arise, discontinue use immediately and consult a physician. There is a risk of pancreatitis, which is inflammation of the pancreas, so symptoms like abdominal pain, vomiting, or persistent nausea should be reported to healthcare professionals immediately. The metformin component of this drug can rarely cause lactic acidosis, a serious metabolic disorder that is very dangerous; symptoms like muscle pain, lethargy, difficulty breathing, or abdominal pain require immediate medical attention. Patients with poor kidney function or those experiencing severe infections, dehydration, or heart issues may be at risk when using this medication, so it is essential to inform the physician if any such conditions are present. This medication should especially not be used in cases of moderate to severe renal impairment or acute heart failure, acute myocardial infarction, or sepsis. Before and after tests involving iodine contrast agents, this medication should be temporarily discontinued due to the risk of worsened kidney function and lactic acidosis, and should be resumed only after confirming normal kidney function post-examination. It is safer for pregnant or potentially pregnant women, as well as nursing mothers, to avoid using this medication. During treatment, irregular meals, excessive exercise, and interactions with other medications can lead to a risk of hypoglycemia, so caution is advised. When taken alongside sulfonylureas or insulin, hypoglycemic symptoms may appear, requiring frequent blood sugar monitoring and potential dosage adjustments after consulting a physician. Additionally, patients with impaired liver function or those who consume alcohol excessively should consult a physician before using this medication due to an increased risk of lactic acidosis. Regular kidney function and blood tests should be conducted during treatment, as vitamin B12 levels may decrease, necessitating periodic testing. Before surgery, discontinue use 48 hours prior, and resume only after confirming normal kidney function and oral intake post-surgery. It is crucial to inform healthcare professionals of any unusual symptoms or discomfort experienced during the use of this medication.

Side effects

Severe hypersensitivity reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory tract infections, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, arthralgia accompanied by severe symptoms and disabilities, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, rash, urticaria, cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, with a recommended storage temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the efficacy and safety of the drug over time.

Appearance and packaging

Appearance

Bright blue, oval-shaped, biconvex sustained-release film-coated tablets

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.